Search 

Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).

WEGO HOLDING COMPANY LIMITED (“WEGO”) was established in March 1988, and it principal business focus on medical devices and pharmaceuticals. In addition, WEGO develops some other business such as real estate and investment. WEGO has 8 industry groups and more than 30 subsidiaries. WEGO Holding's subsidiary ---SHANDONG WEIGAO GROUP MEDICAL POLYMER CO., LIMITED is listed in Hong Kong.

The main products of WEGO are infusion sets, syringes, blood transfusion equipments, heart stents, intracardiac consumables，IV catheters and special needles, blood purification equipments and consumables, orthopedic materials, operating room equipments and accessories, wound care products, minimally invasive instruments and equipments, ICU products and accessories, high-capacity injections and pharmaceuticals, renal products, biological diagnostic reagents, PVC & non-PVC materials and so on. WEGO now has products in more than 30 series, 400 categories and 60,000 specifications products, and has become one of the most reliable suppliers of medical system solutions in the world. At the same time, WEGO actively takes part in healthcare service and provides renal dialysis service.

In addition, under the branding strategy, the WEGO products are sold in more than 30 provinces and municipalities, which covered 81.3% of tertiary hospitals and 77.2% of blood banks in China, and also exported to over 70 countries and areas. WEGO is trying to become an international company, trying to achieve the vision of “To be one of the global elites; Pioneer in Asia; Most respectable medical device and medication enterprise”, and trying to make contributions to China's medical and healthcare industry.

We have, by a wide margin, the safest and most effective nocturia drug. Nocturia leads to over 10,000 deaths per day and costs the US economy $215B/year in lost worktime and lower productivity.  We have the only drug that treats low bladder capacity, which is an issue for 76% of nocturia sufferers.  Our clinical trial results were 5x better than the first FDA approved nocturia drug and 2.5x better than the other FDA approved nocturia drug, both of which carry a black warning about a dangerous blood disorder and have other side effects.  Of course these drugs treat polyuria rather than low bladder capacity, so they are not competitors for our drug.

Listed in China Growth Board, WolwoPharma is the biggest allergen drug manufacturer in China
and the largest allergen preparation supplier in Asia.

Guangzhou Wondfo Biotech Co., Ltd., headquartered in Guangzhou science city, has been focusing on the R&D, production, sales and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic disease management solutions since founded in 1992. Wondfo now has more than 3000 employees and a wide range of products for the rapid identification of cardiovascular diseases, inflammation, tumor, infectious diseases, drug abuse, pregnancy, and so on, widely sold to 140+ countries and regions.

WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.

With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.

A mainland based family fund， heavily investing healthcare and biotechs

The WuXi AppTec Research Services Division (RSD) supports its clients in the discovery and development of future therapeutics. Through comprehensive discovery and technology platforms, peer-recognised scientific leadership and expertise in oncology, immunology, infectious disease, neurosciences, fibrosis, cardiovascular and metabolic disease, RSD works collaboratively to rapidly advance programs from target through to preclinical selection and beyond.

RSD’s discovery platform encompasses biology, chemistry, structural biology and biophysics, in addition to the capabilities of newly acquired HD Biosciences (HDB), and is trusted by over 1,900 international clients, ranging from pharma and biotech to academia and non-profit institutions.

WuXi Apptec provides a broad portfolio of R&D and manufacturing service that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.

Wuxi Biocity is a biopharmaceutical company mainly focusing on discovery, development, clinical trials and commercialization of "Best-in-Class" and "First-in-Class" original new drug of oncology and autoimmune diseases. Established in December 2017 in Wuxi, Biocity aims to benefit patients around the world as a pioneer pharmaceutical company in China with sustainable innovation ability and therapeutic products. With the noble mission of "Better Medicine for Better Life", our team always adhere to scientific evidence, while consider unfulfilled medical needs ahead of time, to achieve the goal of patient-centered, full-lifecycle disease management. Biocity's programs successfully entered into clinical stages within three years of efficient operation.



We are honored to have domestic and international academicians, well-known scientists, enterprise and policy specialists, clinical experts in particular, on our advisory board to guide Biocity's scientific, clinical, and strategic development. To reach our long-term goal of sustainable competitive advantages, we collaborate with the Wuxi government on multiple aspects to establish the "Biocity Innovation Institute for Translational Medicine". Thus we can further dig into the translational medical research from the discovery of disease mechanisms to the therapeutic applications of certain scientific achievements. Biocity Innovation Institute will strengthen our R&D ability and innovation capacity, therefore accelerate the popularization and enhancement of translational medicine in Wuxi, Jiangsu.



We have been recognized by many investment firms and intend to conduct an IPO in the very near future. With great efforts, we will bring safe and effective local innovative medicine at the best of times, to meet the increasing medical needs globally.